Vita 34 AG Stock
Price
Target price
€4.84
€4.84
-1.210%
-0.06
-1.210%
-
25.04.24 / Tradegate
WKN: A0BL84 / Name: Vita 34 / Stock / Healthcare Providers & Services / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Vita 34
sharewise wants to provide you with the best news and tools for Vita 34, so we directly link to the best financial data sources.
Financials
News
EQS-Adhoc: Vita 34 closes 2023 with significantly better results than expected based on preliminary figures
EQS-Adhoc: Vita 34 closes 2023 with significantly better results than expected based on preliminary figures
EQS-Adhoc: Vita 34 publishes preliminary figures on the course of business in 2023
EQS-Adhoc: Vita 34 publishes preliminary figures on the course of business in 2023
EQS-News: Vita 34 downsizes Management Board until further notice
EQS-News: Vita 34 downsizes Management Board until further notice
EQS-Adhoc: Vita 34 AG: resolves on cash capital increase under exclusion of subscription rights in the amount of up to 10% of the share capital, commitments from investors
EQS-Adhoc: Vita 34 AG: resolves on cash capital increase under exclusion of subscription rights in the amount of up to 10% of the share capital, commitments from investors
EQS-News: Vita 34 increases revenue and earnings in Q3 2023 and further stabilizes business development
EQS-News: Vita 34 increases revenue and earnings in Q3 2023 and further stabilizes business development
EQS-Adhoc: Internal investigation by Vita 34 AG reveals irregularities related to a limited number of biological samples at one of its subsidiaries regarding compliance with medical law requirements
EQS-Adhoc: Internal investigation by Vita 34 AG reveals irregularities related to a limited number of biological samples at one of its subsidiaries regarding compliance with medical law requirements